ArticleAnnals of thoracic medicine
Clinical profile of chronic obstructive pulmonary disease patients with and without type 2 inflammation: A comparative study.
Article in Annals of thoracic medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe association between chronic obstructive pulmonary disease (COPD) with type 2 inflammation and comorbidities and functional outcomes remains incompletely defined. We aimed to compare clinical characteristics, comorbidities, and exacerbation risk between COPD patients with and without type 2 inflammation.
methodsThis was a retrospective observational study. Patients with spirometry-confirmed COPD between January 2020 and July 2025 were included. Patients were stratified by serum eosinophil count into type 2 inflammation COPD (≥300 cells/μL) and nontype 2 inflammation COPD (<300 cells/μL). Demographics, comorbidities, pulmonary function, and exacerbation history were assessed. Logistic regression identified independent predictors of exacerbation.
resultsThe total number of patients were 270 (mean age: 70 years; 91.5% of males). Among them, 54.8% had type 2 inflammation COPD. Those with type 2 inflammation had more comorbidities (mean 3 vs. 2;
conclusionCOPD with type 2 inflammation is associated with a higher prevalence of ischemic heart disease and a higher prevalence and higher risk of exacerbation compared with nontype 2 inflammation. Serum eosinophil count is a valuable biomarker for phenotyping and risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.